Palvella Therapeutics Surges on FDA Priority Review for Qtorin

The agency established a Prescription Drug User Fee Act target action date of February 28, 2027, for the drug, chemically identified as rapamycin. Patients suffering from these malformations currently face limited options for managing the skin and oral cysts caused by the underlying genetic mutations.

Palvella Therapeutics specializes in developing novel interventions for rare skin diseases and vascular anomalies that lack existing FDA-cleared treatments. This regulatory designation accelerates the path for Qtorin, signaling potential relief for a patient population that has historically lacked targeted medical support.